| 4.725 -0.195 (-3.96%) | 01-26 14:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.35 |
1-year : | 8.51 |
| Resists | First : | 6.29 |
Second : | 7.28 |
| Pivot price | 5.35 |
|||
| Supports | First : | 4.67 |
Second : | 3.89 |
| MAs | MA(5) : | 4.93 |
MA(20) : | 5.69 |
| MA(100) : | 6.55 |
MA(250) : | 9.01 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 9 |
D(3) : | 11 |
| RSI | RSI(14): 26.6 |
|||
| 52-week | High : | 17.12 | Low : | 4.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EOLS ] has closed above bottom band by 11.8%. Bollinger Bands are 41.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.09 - 5.11 | 5.11 - 5.14 |
| Low: | 4.81 - 4.84 | 4.84 - 4.87 |
| Close: | 4.86 - 4.91 | 4.91 - 4.96 |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Thu, 22 Jan 2026
Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at BTIG Research - MarketBeat
Thu, 15 Jan 2026
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop - simplywall.st
Sun, 11 Jan 2026
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fri, 09 Jan 2026
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue - Business Wire
Fri, 09 Jan 2026
Evolus (EOLS) Achieves Sixth Year of Double-Digit Growth in 2025 - GuruFocus
Wed, 24 Dec 2025
Needham Reiterates Evolus (EOLS) Hold Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 65 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 13.5 (%) |
| Held by Institutions | 84.4 (%) |
| Shares Short | 6,790 (K) |
| Shares Short P.Month | 6,770 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.44 |
| Profit Margin | -20.5 % |
| Operating Margin | -14.8 % |
| Return on Assets (ttm) | -10.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | 2.93 |
| Sales Per Share | 4.4 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -5.25 |
| PEG Ratio | 0 |
| Price to Book value | -10.73 |
| Price to Sales | 1.06 |
| Price to Cash Flow | -6.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|